Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes
- 20 December 2008
- journal article
- leukemia and-bone-marrow-transplantation
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (36) , 5943-5949
Abstract
Purpose: Patients with myelodysplastic syndromes (MDS) often require treatment with growth factors (GFs) or non-GF therapies. One non-GF drug, lenalidomide, is particularly effective at achieving transfusion independence (TI) in patients with lower-risk MDS with the del(5q) cytogenetic abnormality. However, approximately half of del(5q) patients and one quarter of non–del(5q) patients treated with lenalidomide experience significant cytopenias. Lenalidomide-induced cytopenias occurring early in treatment may serve as a surrogate marker of clonal suppression and, therefore, may be predictive of a TI response. Patients and Methods: We analyzed 362 low-risk, transfusion-dependent patients with MDS, with or without the del(5q) abnormality, enrolled in two phase II studies (MDS-003 and MDS-002) to determine whether treatment-related cytopenias are correlated with lenalidomide response. Cytopenias were assessed during the first 8 weeks of therapy, and response was defined as TI; response predictors were explored in univariate and multivariate analyses. Results: Among patients with del(5q), 70% of those whose platelet count decreased by ≥ 50% achieved TI, as compared with 42% of those whose platelet count remained stable or declined by less than 50% (P = .01). Among patients without baseline neutropenia, 82% of those whose absolute neutrophil count (ANC) decreased by ≥ 75% achieved TI, as compared with 51% whose ANC remained stable or decreased by less than 75% (P = .02). These relationships were consistent in multivariate analyses. No relationship between the development of cytopenias and response could be established for lower-risk patients with MDS without del(5q). Conclusion: These findings support the hypothesis that a direct cytotoxic effect of lenalidomide specific to the del(5q) clone may be indicative of a TI response.Keywords
This publication has 34 references indexed in Scilit:
- Identification of RPS14 as a 5q- syndrome gene by RNA interference screenNature, 2008
- Myelodysplastic syndromesCancer, 2007
- High-Resolution Genomic Arrays Facilitate Detection of Novel Cryptic Chromosomal Lesions in Myelodysplastic SyndromesExperimental Hematology, 2007
- Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemiaBlood, 2006
- Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBlood, 2006
- Arsenic Trioxide in Patients With Myelodysplastic Syndromes: A Phase II Multicenter StudyJournal of Clinical Oncology, 2006
- Phase II Multicenter Study of Arsenic Trioxide in Patients With Myelodysplastic SyndromesJournal of Clinical Oncology, 2006
- Decitabine improves patient outcomes in myelodysplastic syndromesCancer, 2006
- Myelodysplastic SyndromesHematology-American Society Hematology Education Program, 2004
- Immunomodulation by thalidomide and thalidomide analoguesAnnals of the Rheumatic Diseases, 1999